5,5-Tetramethylen-2-oxo-1,3-dioxan | 40998-21-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 5,5-Tetramethylen-2-oxo-1,3-dioxan
• 英文别名: 7,9-dioxa-spiro[4.5]decan-8-one；7,9-dioxaspiro[4.5]decan-8-one
• CAS: 40998-21-8
• 化学式: C₈H₁₂O₃
• 分子量: 156.181
• InChiKey: FABAOOULXYDANF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,5-Tetramethylen-2-oxo-1,3-dioxan 、 (S)-O-(2,6-dichlorobenzyl)tyrosine methyl ester hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 17.0h， 生成 N-[(1-carboxymethyl)cyclopentaneacetyl]-O-[(2,6-dichlorophenyl)methyl]-L-tyrosine methyl ester
  参考文献：
  名称：

  INHIBITORS OF ALPHA-4 BETA-1 MEDIATED CELL ADHESION

  摘要：

  公开号：

  EP1144365B1

文献信息

• CYCLIC CARBONATE MONOMER CONTAINING DOUBLE-SULFUR FIVE-MEMBERED RING FUNCTIONAL GROUP, AND PREPARATION METHOD THEREOF
  申请人：Bright Gene Bio-Medical Technology Co., Ltd.

  公开号：EP3150611A1

  公开（公告）日：2017-04-05

  Disclosed are a cyclic carbonate monomer containing a double-sulfur five-membered ring functional group, and preparation method thereof. The cyclic carbonate monomer can be simply and efficiently synthesized without protection and deprotection processes. The cyclic carbonate monomer of the present invention can be utilized to obtain polycarbonate having a controllable molecular weight and molecular weight distribution via ring opening polymerization, and has biodegradability and reduction-sensitive reversible crosslinking properties. The present invention can be used in a carrier having controllably released drug, a biological tissue scaffold or a biochip.

  本发明公开了一种含有双硫五元环官能团的环状碳酸酯单体及其制备方法。本发明的环状碳酸酯单体可以简单高效地合成，无需保护和去保护过程。本发明的环状碳酸酯单体可用于通过开环聚合获得分子量和分子量分布可控的聚碳酸酯，并具有生物降解性和还原敏感的可逆交联特性。本发明可用于具有可控释放药物的载体、生物组织支架或生物芯片。
• [EN] INHIBITORS OF alpha 4 beta 1 MEDIATED CELL ADHESION<br/>[FR] INHIBITEURS DE L'ADHESION CELLULAIRE INDUITE PAR alpha 4 beta 1
  申请人：TANABE SEIYAKU CO

  公开号：WO2000037429A2

  公开（公告）日：2000-06-29

  The present invention relates to small molecules according to formula (I) which are potent inhibitors of a α4β1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing α4β1 adhesion mediated conditions in a mammal such as a human.